No generics without originals or do we need innovation at all? Robert Gal MD

R&D process of a new compound No of compounds in the process Time to market is 15 years without the reimbursement obtained patent is years from the 1 st registration in the world Registration timelines in Serbia? Market access with reimbursement in Serbia? How many years is left to an original molecule in Serbia?

R&D spending of the industry

Generic – original shares in different European countries

Serbian market is quite advanced regarding generic penetration Due to the very low price level spending on generics is already higher

Costs are driven by the disease prevalence ! - Oncology still will drive the costs Increasing disease prevalence –Diabetes –Movement disorders –CNS Life expectancy is increasing The number of years spent without a disease is NOT!

The structure of RZZO expenditures – based on IMS sales and reimbursement levels What is the strategy behind the expenditures? What are the priority therapy areas? What are the rationalities behind level of reimbursements?